not diabetic

not diabetic的基本解释

-

[医]非糖尿病的, 非糖尿病患者

与not diabetic相关的网络例句 [注：此内容来源于网络，仅供参考]

In the experiment, an approach was made to the cause of DRP and the mechanism of it's prevention and treatmend by acupuncture. The experimental results indicated that in rat with diabetes,(1) plasma TXB2 and the ratio of TXB2 to 6-keto-PGF1α increased obviously, suggesting hyperfunction of platelet and injury to endothelial function, which tend to result in thrombosis;(2) erythrocytic filtration index increased remarkably, suggesting erythrocytic transforming and oxygen carring hypofunction, which is one of the factors leading to retinal anoxia;(3) hyperglycemia persisted, which is related to the thickening of basilar membrane of and the decrease of mural cell of retinal blood vessels;(4) serum growth hormone rose notably, which is not only one of the important factors causing basilar membrane thickening but also promotes the synthesis or Von Willebrand Factor that participates in a tendency to thrombosis.

本实验对糖尿病性视网膜病变（Diabetic Retinopathy，DRP）的成因以及针刺防治DRP的作用机理进行了探讨，实验结果表明：糖尿病大鼠（1）血浆TXB2及TXB2/6-ket0-PGF1α比值均显著升高，提示其血小板机能亢进，内皮细胞功能损伤，具有血栓形成倾向；（2）红细胞滤过指数（Filtration Index，IF）显著增高，提示其红细胞变形能力低下，携氧运行功能降低，是造成视网膜缺氧状态的因素之一；（3）呈持续高血糖状态，与视网膜血管基底膜增厚及管壁细胞减少有关；（4）血清生长激素（Growth Hormone，GH）水平明显升高，既是导致基底膜增厚的重要因素之一，又促进VWF合成，参与血栓形成倾向。

And they have not diabetic, hyperlipidemia, gloucoma and deformity of the retinal vessel or nerve tissue. All patients were examined by the most advanced presantly Herdbeg-II fluorescin Angiography system.

采用目前世界上最先进的海德堡Ⅱ型共焦激光眼底造影系统；以该系统自带软件测量黄斑无血管区上下径和左右径；Potoshop7.0软件分析测量动脉分支角度；以SPSS 11.5为统计软件。

PPAR γ agonist displayed obvious renoprotective action,the mechanism was complicated, it could improve the metabolism of glucose ang lipid, depress blood preasure, protect small vessels endothelium,improve the system activity of blood clotting and fibronolysis, antiinflammation, otherwise the action was more obvious with the time passed, at the early stage the effective was better,so encourage the patients to take the medicine earily; when the patients with the mediate reanl function failure, Avandia did not display significantly renoprotective action, side reaction had no difference compared to the control group,was not necessary to regulate the dose of Avandia.But because of the sample size was small, we needed a biger sample to confirm the results. We confirmed that Prol2Ala had no difference in control case,diabetic nephropathy group and diabete group,In diabetic group and diabetic nephropathy group, Ala carriers compared to noncarrier all kinds of biochemical indicators were not different,Prol2Ala did not have association with diabete and diabetic nephropathy. But because of the sample size was small, weneeded a biger sample to confirm the results.

PPARγ激动剂对糖尿病肾病具有明显的保护作用，保护作用的机制是多方面的，除了改善糖脂代谢，降低血压外，还具有保护小血管内皮，改善凝血和纤溶系统活性，抗炎症等多方面的作用，且作用随着用药时间的延长而日趋明显，在疾病的早期应用效果更佳，故提倡早期用药；对伴有慢性肾功不全的患者，罗格列酮对肾脏靶器官的保护作用显现的并不明显，但副作用与对照组无明显差异，不用根据肾功情况调整用药，但由于样本量较小，上述结论尚需大样本进行进一步证实；本实验研究得出Prol2Ala变异在健康对照组、糖尿病组及糖尿病肾病组均无显著差异，糖尿病组及糖尿病肾病组临床各生化指标与Prol2Ala变异亦无相关性，Prol2Ala与糖尿病及糖尿病肾病不相关。